These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 12872461)

  • 1. [Efficiency of diovan (valsartane) in arterial hypertension patients].
    Novokrestova SV; Salamatina LV; Buganov AA; Umanskaia EL; Shesterikova NV; Mamedova SI
    Med Tr Prom Ekol; 2003; (4):28-32. PubMed ID: 12872461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and tolerance of ACE inhibitor invoril and angiotensin I At-receptor blocker diovan in patients with stages I-II of arterial hypertension].
    Nesterov IuI; Tepliakov AT; Spoeva VI
    Klin Med (Mosk); 2002; 80(8):46-9. PubMed ID: 12360620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diovan effectiveness in combined treatment of severe arterial hypertension].
    Bichan NA; Maslov AP
    Ter Arkh; 2000; 72(8):34-6. PubMed ID: 11019424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diovan efficacy and tolerance in mild and moderate hypertension].
    Zakirova AN; Zakirova NE
    Ter Arkh; 1999; 71(4):41-4. PubMed ID: 10358862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of valsartan and perindopril in the treatment of essential hypertension in the malaysian population.
    Bavanandan S; Morad Z; Ismail O; Chandran A; Thayaparan T; Singaraveloo M
    Med J Malaysia; 2005 Jun; 60(2):158-62. PubMed ID: 16114156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The hypotensive effect and tolerance of valsartan (Diovan) in hypertension in a general clinical practice].
    Ivleva AIa; Sokolova MA; Moiseev VS
    Ter Arkh; 1999; 71(2):67-70. PubMed ID: 10222559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [24-hour arterial hypertension profile and heart rhythm variability in patients with arterial hypertension and NIDDM].
    Borovkov NN; Sidorova NV
    Klin Med (Mosk); 2002; 80(7):19-21. PubMed ID: 12181808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New prospects in the treatment of arterial hypertension. Antagonist of angiotensin II valsartan (diovan)].
    Ivleva AIa
    Ter Arkh; 1998; 70(9):85-8. PubMed ID: 9821238
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
    Ledingham JM; Laverty R
    Clin Exp Pharmacol Physiol; 2005; 32(1-2):76-85. PubMed ID: 15730439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
    White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L
    Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
    Hermida RC; Ayala DE; Khder Y; Calvo C
    Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].
    Rodríguez Pérez JC; Novoa Novoa J; Caballero A; Anabitarte A; Plaza C; Palop L; Rodríguez Esparragón F
    Nefrologia; 2005; 25(5):500-8. PubMed ID: 16392299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S; Liu Y; Wang L; Meng QH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.